Glucagon (19-29), human

Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

Product Specifications

CAS Number

[64790-15-4]

UNSPSC

12352209

Target

GCGR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Glucagon__19-29_,_human.html

Purity

99.11

Solubility

DMSO : ≥ 25 mg/mL|H2O : 1.25 mg/mL (ultrasonic; adjust pH to 9 with NH3·H2O)

Smiles

O=C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CC(N)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)=O)=O)[C@@H](NC([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@@H](NC([C@H](CC(O)=O)NC([C@H](CCC(N)=O)NC([C@@H](N)C)=O)=O)=O)CC1=CC=CC=C1)=O)=O)=O)CC2=CNC3=C2C=CC=C3

Molecular Formula

C61H89N15O18S

Molecular Weight

1352.53

References & Citations

[1]Dalle S, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274 (16) :10869-76.|[2]Dalle S, et al. Miniglucagon (glucagon 19-29) : a novel regulator of the pancreatic islet physiology. Diabetes. 2002 Feb;51 (2) :406-12.|[3]Pavoine C, et al. Miniglucagon [glucagon- (19-29) ] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260 (5 Pt 1) :C993-9.